Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
32
BPTH Quote, Financials, Valuation and Earnings
Last price:
$1.06
Seasonality move
:
28.02%
Day range:
$1.07 - $1.22
52-week range:
$0.59 - $12.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.95x
Volume:
321.1K
Avg. volume:
4.2M
1-year change:
-90.16%
Market cap:
$4.7M
Revenue:
--
EPS (TTM):
-$11.03
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Bio-Path Holdings has 1000.92% upside to fair value with a price target of -- per share.
BPTH vs. S&P 500
-
Over the past 5 trading days, Bio-Path Holdings has underperformed the S&P 500 by -5.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Path Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Path Holdings has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Bio-Path Holdings reported revenues of --.
Earnings Growth
-
Bio-Path Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Bio-Path Holdings reported earnings per share of -$0.70.
Enterprise value:
4.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$14M | -$16.8M | -$12.4M | -$3.3M | -$2.6M | |
| EBITDA | -$13.9M | -$16.6M | -$12.2M | -$3.2M | -$2.6M | |
| Diluted EPS | -$39.40 | -$40.77 | -$11.03 | -$6.36 | -$0.70 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $14.3M | $30.2M | $18.1M | $4.8M | $2.9M | |
| Total Assets | $14.9M | $30.7M | $18.5M | $5M | $3M | |
| Current Liabilities | $1.4M | $1.2M | $2.2M | $1.4M | $3.4M | |
| Total Liabilities | $1.7M | $1.3M | $2.3M | $2.5M | $3.7M | |
| Total Equity | $13.2M | $29.3M | $16.2M | $2.5M | -$712K | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$12.9M | -$14.7M | -$9.5M | -$2.8M | -$3.4M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $3.4M | $7.7M | $1.7M | -$16K | |
| Free Cash Flow | -$12.9M | -$14.7M | -$9.5M | -$2.8M | -$3.4M | |
BPTH
Sector
Market Cap
$4.7M
$48.9M
Price % of 52-Week High
9.08%
49.34%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-90.16%
-30.56%
Beta (5-Year)
0.083
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.16
200-day SMA
Sell
Level
$1.76
Bollinger Bands (100)
Buy
Level
0.78 - 1.2
Chaikin Money Flow
Sell
Level
-452.4M
20-day SMA
Buy
Level
$0.96
Relative Strength Index (RSI14)
Buy
Level
54.11
ADX Line
Buy
Level
43.59
Williams %R
Buy
Level
-83.6698
50-day SMA
Buy
Level
$0.91
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
835.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Stock Forecast FAQ
In the current month, BPTH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BPTH average analyst price target in the past 3 months is --.
-
Where Will Bio-Path Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Path Holdings share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Bio-Path Holdings?
Analysts are divided on their view about Bio-Path Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Path Holdings is a Sell and believe this share price will drop from its current level to --.
-
What Is Bio-Path Holdings's Price Target?
The price target for Bio-Path Holdings over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BPTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Path Holdings is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BPTH?
You can purchase shares of Bio-Path Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Path Holdings shares.
-
What Is The Bio-Path Holdings Share Price Today?
Bio-Path Holdings was last trading at $1.06 per share. This represents the most recent stock quote for Bio-Path Holdings. Yesterday, Bio-Path Holdings closed at $1.09 per share.
-
How To Buy Bio-Path Holdings Stock Online?
In order to purchase Bio-Path Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
42
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 125x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
NARI alert for Jan 7
Inari Medical [NARI] is up 22.25% over the past day.
Buy
70
PDEX alert for Jan 7
Pro-Dex [PDEX] is down 10.89% over the past day.
Buy
52
ALCO alert for Jan 7
Alico [ALCO] is down 3.89% over the past day.
